China Shineway Pharmaceutical GroupCSWYY 92 Peter Lynch Fair Value is $46.34 as of Jul. 03, 2026, which is 6816% above its 10-year median of 0.67. GuruFocus rates CSWYY with a GF Score™ of 92/100 and a GF Value™ of $17.28. The stock has 2 warning signs investors should review. Among 265 Drug Manufacturers companies, China Shineway Pharmaceutical Group ranks better than 92.08% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
The historical rank and industry rank for China Shineway Pharmaceutical Group's Peter Lynch Fair Value or its related term are showing as below:
CSWYY'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.41 Med: 0.67 Max: 1.3
Current: 0.41
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of China Shineway Pharmaceutical Group was 1.30. The lowest was 0.41. And the median was 0.67.
CSWYY's Price-to-Peter-Lynch-Fair-Value is ranked better than 92.08% of 265
companies
in the Drug Manufacturers industry
Industry Median: 1.31
vs CSWYY: 0.41
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
China Shineway Pharmaceutical Group (OTCPK:CSWYY) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 12.6 instead of 15 in this case.
China Shineway Pharmaceutical Group's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
19.25
/
46.34
=
0.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group Peter Lynch Fair Value Related Terms
China Shineway Pharmaceutical Group Peter Lynch Fair Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group Peter Lynch Fair Value Chart
CSWYY vs ZTS, UTHR: Peter Lynch Fair Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group Price-to-Peter-Lynch-Fair-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's Price-to-Peter-Lynch-Fair-Value falls into.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Shineway Pharmaceutical Group's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $3.68.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of $46.34 mean?
China Shineway Pharmaceutical Group (CSWYY) has a Peter Lynch Fair Value of $46.34 as of Jul. 03, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on China Shineway Pharmaceutical Group and its competitors. This is 6816% above median its historical median of 0.67. Over the past decade, China Shineway Pharmaceutical Group's Peter Lynch Fair Value has ranged from 0.41 to 1.30. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #21 out of 265 companies in the Drug Manufacturers industry, placing it in the top 7.9%.
Is China Shineway Pharmaceutical Group's Peter Lynch Fair Value too high?
China Shineway Pharmaceutical Group's current Peter Lynch Fair Value of $46.34 is 6816% above median its 10-year median of 0.67. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 1.30. The Drug Manufacturers industry median Peter Lynch Fair Value is 1.31. China Shineway Pharmaceutical Group's value of $46.34 is 3437.4% above this industry median. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #21 out of 265 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's Peter Lynch Fair Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #21 out of 265 companies for Peter Lynch Fair Value. This places China Shineway Pharmaceutical Group in the top 8% of its industry — outperforming the majority of peers. The industry median Peter Lynch Fair Value is 1.31. China Shineway Pharmaceutical Group's value of $46.34 is 3437.4% above this benchmark. Historically, China Shineway Pharmaceutical Group's own Peter Lynch Fair Value has ranged from 0.41 to 1.30 over the past decade. While the company's 10-year median is 0.67 vs. the industry median of 1.31, China Shineway Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Drug Manufacturers company?
The median Peter Lynch Fair Value among Drug Manufacturers companies is 1.31, based on 265 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Shineway Pharmaceutical Group's current Peter Lynch Fair Value of $46.34 is 3437.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on China Shineway Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Peter Lynch Fair Value is 1.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current Peter Lynch Fair Value is $46.34, which is 6816% above median its own 10-year median of 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYY) has a current Peter Lynch Fair Value of $46.34. The stock's GF Value™ is $17.28, compared to a current price of $19.25 — trading 11.4% above its estimated fair value. The current Peter Lynch Fair Value is $46.34, which is 6816% above median its 10-year median of 0.67 and 3437.4% above the Drug Manufacturers industry median of 1.31. China Shineway Pharmaceutical Group's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYY), the current Peter Lynch Fair Value is $46.34 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (CSWYY) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of $19.25 is trading 11.4% above its estimated GF Value™ of $17.28.
Key valuation signals for CSWYY:
Peter Lynch Fair Value: $46.34 (6816% above median its 10-year median of 0.67)
GF Value™: $17.28 vs. price of $19.25 (11.4% above fair value)
Industry Position: 3437.4% above the Drug Manufacturers median (#21 of 265)
No single metric tells the full story. See the CSWYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Business Description
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
92GF Score
Get the complete analysis for CSWYY
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSWYY has been successfully added to your 
